- Home
- DTIL vs COEP Comparison
DTIL vs COEP Comparison
Compare DTIL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | COEP |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.0M | 100.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DTIL | COEP |
|---|---|---|
| Price | $4.76 | $15.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $47.00 | N/A |
| AVG Volume (30 Days) | ★ 256.9K | 72.9K |
| Earning Date | 11-03-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $698,000.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.61 | $2.31 |
| 52 Week High | $8.82 | $21.41 |
Technical Indicators
Market Signals| Indicator | DTIL | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 46.35 |
| Support Level | $4.70 | $15.40 |
| Resistance Level | $5.20 | $16.80 |
| Average True Range (ATR) | 0.38 | 1.48 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 7.02 | 6.60 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.